

Roberta D'ambrosio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7190254/publications.pdf>

Version: 2024-02-01

89
papers

3,591
citations

201674

27
h-index

138484

58
g-index

89
all docs

89
docs citations

89
times ranked

5082
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. <i>Journal of Hepatology</i> , 2022, 76, 302-310.	3.7	48
2	Prothrombin induced by vitamin K absence or antagonist and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 350-359.	3.7	11
3	Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study. <i>Hepatology Communications</i> , 2022, 6, 867-877.	4.3	6
4	Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: A case series. <i>Liver International</i> , 2022, 42, 864-870.	3.9	8
5	Implementation of HCV screening in the 1969-1989 birth cohort undergoing COVID-19 vaccination. <i>Liver International</i> , 2022, 42, 1012-1016.	3.9	13
6	Is it time to refine HCC surveillance strategies in HCV cured patients?. <i>Hepatology</i> , 2022, 76, 9-11.	7.3	2
7	Editorial: the role for PIVKA measurement after HCV elimination by direct-acting antivirals in terms of prediction of hepatocellular carcinoma authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 124-125.	3.7	0
8	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2008-e2020.	3.6	27
9	Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19. <i>Gut</i> , 2021, 70, 1798-1799.	12.1	1
10	Suboptimal accuracy of GES score to stratify post-SVR HCC risk in a single center cohort of European cirrhotics infected with any HCV genotype. <i>Liver International</i> , 2021, 41, 1152-1153.	3.9	7
11	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021, 74, 775-782.	3.7	193
12	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. <i>Journal of Viral Hepatitis</i> , 2021, 28, 558-568.	2.0	3
13	Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal β -Blocker Therapy. <i>American Journal of Gastroenterology</i> , 2021, 116, 1342-1344.	0.4	12
14	The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD). <i>PLoS ONE</i> , 2021, 16, e0249614.	2.5	15
15	Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 713-739.	3.7	10
16	A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1443-1451.	2.0	1
17	The CCR5 and CXCR3 Pathways in Hepatitis C Virus Liver Transplanted Recipients Treated by a Direct Antiviral Agent Regimen: Informative Kinetics Profiles. <i>Viral Immunology</i> , 2021, 34, 542-551.	1.3	2
18	Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication. <i>Hepatology Communications</i> , 2021, 5, 1465-1468.	4.3	1

#	ARTICLE	IF	CITATIONS
19	Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. <i>Hepatology Communications</i> , 2021, 5, 1824-1832.	4.3	37
20	Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy. <i>JHEP Reports</i> , 2020, 2, 100062.	4.9	42
21	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. <i>Digestive and Liver Disease</i> , 2020, 52, 190-198.	0.9	12
22	High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study. <i>Liver International</i> , 2020, 40, 1062-1068.	3.9	13
23	Hepatic Fatâ€”Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. <i>Hepatology</i> , 2020, 72, 1912-1923.	7.3	48
24	Reply to: Correspondence on â€œHigh rates of 30-day mortality in patients with cirrhosis and COVID-19â€• <i>Journal of Hepatology</i> , 2020, 73, 1570-1571.	3.7	10
25	High rates of 30-day mortality in patients with cirrhosis and COVID-19. <i>Journal of Hepatology</i> , 2020, 73, 1063-1071.	3.7	279
26	Liver damage and sickle cell disease: genotype relationship. <i>Annals of Hematology</i> , 2020, 99, 2065-2072.	1.8	7
27	Comparison of three therapeutic regimens for genotypeâ€³ hepatitis C virus infection in a large real-life multicentre cohort. <i>Liver International</i> , 2020, 40, 769-777.	3.9	15
28	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 593-602.	3.7	38
29	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.	4.2	8
30	THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy. <i>Journal of Hepatology</i> , 2019, 70, e234-e235.	3.7	1
31	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. <i>Liver International</i> , 2019, 39, 2309-2316.	3.9	8
32	Assessing spleen stiffness by point shear-wave elastography: Is it feasible and reproducible in patients with chronic liver disease? Is it useful to predict portal hypertension?. <i>GastroHep</i> , 2019, 1, 205-213.	0.6	3
33	TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1233-1236.	2.0	10
34	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 3682.	3.3	85
35	Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients. <i>Kidney International</i> , 2019, 95, 993-995.	5.2	1
36	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-Î²1 dependent mechanisms. <i>Scientific Reports</i> , 2019, 9, 1439.	3.3	7

#	ARTICLE	IF	CITATIONS
37	Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study. <i>Transplant International</i> , 2019, 32, 493-501.	1.6	9
38	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2019, 70, 379-387.	3.7	109
39	Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1183-1191.e7.	4.4	79
40	Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage. <i>Viral Immunology</i> , 2018, 31, 358-361.	1.3	1
41	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to <sc>IFN</sc> and cirrhosis regression. <i>Liver International</i> , 2018, 38, 1459-1467.	3.9	22
42	12 weeks ombitasvir/paritaprevir+ritonavir+asunaprevir/sofosbuvir achieve high SVR rates in HCV-4 patients with advanced fibrosis. <i>Digestive and Liver Disease</i> , 2018, 50, 703-706.	0.9	0
43	Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. <i>Liver International</i> , 2017, 37, 1295-1303.	3.9	18
44	Direct-acting antivirals: the endgame for hepatitis C?. <i>Current Opinion in Virology</i> , 2017, 24, 31-37.	5.4	81
45	Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. <i>American Journal of Hematology</i> , 2017, 92, 1349-1355.	4.1	42
46	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2017, 66, 485-493.	3.7	225
47	Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. <i>PLoS ONE</i> , 2016, 11, e0155967.	2.5	23
48	Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. <i>Hepatology</i> , 2016, 63, 827-838.	7.3	467
49	Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?. <i>Hepatology</i> , 2016, 64, 322-323.	7.3	0
50	Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?. <i>Liver International</i> , 2016, 36, 783-790.	3.9	29
51	Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature. <i>Liver International</i> , 2016, 36, 1585-1589.	3.9	22
52	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. <i>Digestive and Liver Disease</i> , 2016, 48, 650-655.	0.9	11
53	P143: Concordance between SVR4 and SVR24 in DAA Based Regimens: a real life experience including post-liver transplant patients. <i>Journal of Viral Hepatitis</i> , 2015, 22, 91-92.	2.0	0
54	Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 19698-19712.	4.1	57

#	ARTICLE	IF	CITATIONS
55	Treating hepatitis C in patients with hemoglobinopathies. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1267-1278.	0.8	0
56	Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 473-484.	2.4	9
57	Statins May Increase the Risk of Liver Dysfunction in Patients Treated With Steroids for Active Graves' Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1731-1737.	3.6	12
58	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. <i>Hepatology</i> , 2015, 62, 111-117.	7.3	52
59	Contribution of β -cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. <i>Journal of Hepatology</i> , 2015, 63, 1484-1490.	3.7	61
60	Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity. <i>PLoS ONE</i> , 2015, 10, e0138546.	2.5	14
61	Telaprevir in a Patient with Chronic Hepatitis C and Cryoglobulinemic Glomerulonephritis. <i>Antiviral Therapy</i> , 2014, 19, 527-531.	1.0	18
62	Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir. <i>PLoS ONE</i> , 2014, 9, e95881.	2.5	13
63	Acute Allograft Rejection following Interferon Therapy for Hepatitis C in Recipients who have Returned to Dialysis after Kidney Transplant Failure: Case Study. <i>International Journal of Artificial Organs</i> , 2014, 37, 803-808.	1.4	2
64	The Association of IL28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent. <i>International Journal of Molecular Sciences</i> , 2014, 15, 7213-7224.	4.1	19
65	De Novo Membrano-Proliferative Nephritis Following Interferon Therapy for Chronic Hepatitis C (Case Study and Literature Review). <i>Digestive Diseases and Sciences</i> , 2014, 59, 691-695.	2.3	5
66	Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e106022.	2.5	9
67	Safety of direct antiviral agents in real life. <i>Digestive and Liver Disease</i> , 2013, 45, S363-S366.	0.9	14
68	The diagnostic accuracy of Fibroscan [®] for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. <i>Journal of Hepatology</i> , 2013, 59, 251-256.	3.7	131
69	Acute Tubular Necrosis Following Interferon-Based Therapy for Hepatitis C: Case Study with Literature Review. <i>Kidney and Blood Pressure Research</i> , 2013, 38, 52-60.	2.0	12
70	Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. <i>Journal of Viral Hepatitis</i> , 2013, 20, 858-866.	2.0	32
71	Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. <i>Hepatology</i> , 2013, 58, 1245-1252.	7.3	69
72	Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks. <i>Hepatitis Monthly</i> , 2012, 12, 361-368.	0.2	9

#	ARTICLE	IF	CITATIONS
73	Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. <i>Biologics: Targets and Therapy</i> , 2012, 6, 363.	3.2	1
74	Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. <i>Hepatology</i> , 2012, 56, 1681-1687.	7.3	83
75	Hyporesponsiveness to PegIFN α 2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. <i>Journal of Hepatology</i> , 2012, 56, 341-347.	3.7	21
76	Proteomics to Predict Hepatitis C Therapy Outcome: Where Do We Stand?. <i>Gastroenterology</i> , 2012, 142, 1034-1037.	1.3	0
77	A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. <i>Hepatology</i> , 2012, 56, 532-543.	7.3	354
78	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. <i>Hepatology</i> , 2012, 55, 336-342.	7.3	81
79	The Course of Esophageal Varices in Patients with Hepatitis C Cirrhosis Responding to Interferon/Ribavirin Therapy. <i>Antiviral Therapy</i> , 2011, 16, 677-684.	1.0	48
80	Ribavirin Impairs Salivary Gland Function in Hepatitis C Patients During Combination Treatment With Pegylated Interferon Alfa-2a. <i>Hepatitis Monthly</i> , 2011, 11, 918-924.	0.2	10
81	Randomized Study of Peginterferon α 2a Plus Ribavirin vs Peginterferon α 2b Plus Ribavirin in Chronic Hepatitis C. <i>Gastroenterology</i> , 2010, 138, 108-115.	1.3	190
82	The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. <i>Antiviral Therapy</i> , 2009, 14, 577-84.	1.0	16
83	The pattern of pegylated interferon α 2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. <i>Antiviral Therapy</i> , 2009, 14, 577-584.	1.0	30
84	Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. <i>Antiviral Therapy</i> , 2007, 12, 1033-40.	1.0	2
85	Lack of Rapid Virological Response Predicts Interferon α 2b/Ribavirin Therapy failure in HCV Genotype 2 Patients: A Single-Centre Study. <i>Antiviral Therapy</i> , 2007, 12, 1033-1040.	1.0	8
86	The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. <i>Journal of Hepatology</i> , 2006, 44, 825.	3.7	2
87	A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: The interferon-inducible gene IFI16. <i>Arthritis and Rheumatism</i> , 2006, 54, 3939-3944.	6.7	64
88	Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. <i>Antiviral Therapy</i> , 2006, 11, 797-802.	1.0	6
89	Impaired Response to Interferon α 2B plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection. <i>Antiviral Therapy</i> , 2006, 11, 797-802.	1.0	15